GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR
05 Juin 2024 - 2:30PM
Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a
medical technology company focused on the design, development, and
commercialization of novel technologies for people with diabetes,
today announced that it has successfully completed a second
long-term preclinical study for its Continuous Blood Glucose
Monitor (CBGM). This study further validates the CBGM’s sustained
accuracy and performance with a Mean Absolute Relative Difference
(MARD) of 4.7% at Day 90, which is considered highly accurate for a
continuous glucose monitor.
MARD is a key metric used to assess the accuracy
of glucose monitoring devices, measuring the average difference
between the CBGM device’s measurement and a reference measurement,
most often obtained via capillary blood glucose. Lower values
indicate better performance.
Glucotrack’s CBGM measures glucose in the blood,
without the lag time associated with subcutaneous sensors that
measure glucose in interstitial fluid. The ability to directly
measure blood glucose in real time and on a continuous basis
enables a less burdensome approach to glucose monitoring for
extended periods of time.
The 90-day preclinical study, which included a
larger number of animal subjects and a longer duration than the
initial 60-day study announced earlier this year, further validates
the CBGM’s sustained accuracy and performance. The study
incorporated periodic glucose tolerance testing to compare the
performance of the Glucotrack CBGM against both a commercially
available blood glucose monitor and a subcutaneous continuous
glucose monitor. The study was completed with no significant
adverse effects.
“We are again very pleased with the performance
of our sensor during a long-term preclinical study and look forward
to moving into human clinical trials” stated Paul Goode, PhD, CEO
of Glucotrack. “Our CBGM’s ability to continuously measure blood
glucose for 2+ years with accuracy, minimal calibration and without
a wearable device represents a significant advancement in glucose
monitoring. We believe this technology has the potential to greatly
improve the quality of life for people with diabetes by providing a
more convenient and discreet monitoring solution.”
Glucotrack previously announced that it had
completed preclinical animal testing in an acute setting and had
initiated a long-term animal study to assess sustained glucose
monitoring performance. The CBGM prototypes used in this study were
manufactured using refined production techniques that bring the
device closer to the commercially desired product. The Company
plans to initiate human clinical trials later this year.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on
the design, development, and commercialization of novel
technologies for people with diabetes. The Company is currently
developing a long-term implantable continuous blood glucose
monitoring system for people living with diabetes.
Glucotrack’s CBGM is a long-term, implantable
system that continually measures blood glucose levels with a sensor
longevity of 2+ years, no on-body wearable component and with
minimal calibration. For more information, please
visit http://www.glucotrack.com. Information on the Company’s
website does not constitute a part of and is not incorporated by
reference into this news release.
Forward-Looking Statements
This news release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements contained in this news release that
are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the generality of the
foregoing, words such as “believe”, “expect”, “plan” and “will” are
intended to identify forward-looking statements. Such
forward-looking statements are based on the beliefs of management,
as well as assumptions made by, and information currently available
to, management. These statements relate only to events as of the
date on which the statements are made, and Glucotrack undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law. All of the forward-looking statements
made in this press release are qualified by these cautionary
statements, and there can be no assurance that the actual results
anticipated by Glucotrack will be realized or, even if
substantially realized, that they will have the expected
consequences to or effects on us or our business or operations.
Readers are cautioned that certain important factors may affect
Glucotrack’s actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect Glucotrack’s results
include, but are not limited to, the ability of Glucotrack to raise
additional capital to finance its operations (whether through
public or private equity offerings, debt financings, strategic
collaborations or otherwise); risks relating to the receipt (and
timing) of regulatory approvals (including U.S. Food and Drug
Administration approval); risks relating to enrollment of patients
in, and the conduct of, clinical trials; risks relating to
Glucotrack’s future distribution agreements; risks relating to its
ability to hire and retain qualified personnel, including sales and
distribution personnel; and the additional risk factors described
in Glucotrack’s filings with the U.S. Securities and Exchange
Commission (the “SEC”), including its Annual Report on Form 10-K
for the year ended December 31, 2023 as filed with the SEC on March
28, 2024.
Contacts:
Investor Relations:investors@glucotrack.com
Media:GlucotrackPR@icrinc.com
GlucoTrack (NASDAQ:GCTK)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
GlucoTrack (NASDAQ:GCTK)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024